Antigingivitis activity

Antigingivitis activity refers to the therapeutic capacity of a substance or intervention to prevent, reduce, or reverse inflammation of the gingival tissues. It is not a specific molecular target, such as a protein receptor or enzyme, but rather a clinical outcome or pharmacological property commonly associated with oral care products like mouthwashes and toothpastes [9, 11]. This activity is primarily characterized by the ability to disrupt the accumulation of dental plaque biofilm—the primary etiologic driver of gingivitis—and to modulate the local immune response to bacterial challenge [8, 15]. Key agents such as chlorhexidine gluconate and stannous fluoride provide this activity by inhibiting microbial growth, preventing bacterial attachment to tooth surfaces, and dampening the levels of tissue-destructive enzymes and inflammatory cytokines [10, 13]. In clinical research, antigingivitis efficacy is objectively quantified using standardized indices such as the Gingival Index (GI) and measures of Bleeding on Probing (BOP) [3, 4].

Other names

Anti-gingival inflammation activityGingival health promotionGingivitis reductionPlaque control activity

Antigingivitis activity is achieved through the reduction of dental plaque biofilm and the suppression of the host's inflammatory response in the gingival tissues [8, 11]. Antimicrobial agents exert bactericidal or bacteriostatic effects on key oral pathogens, such as Porphyromonas gingivalis, by disrupting bacterial cell membranes, increasing permeability, or interfering with metabolic enzymes [10, 15]. Furthermore, these agents can prevent the initial adherence of bacteria to the salivary pellicle on tooth surfaces and inhibit the production of pro-inflammatory mediators, including cytokines (IL-1β, IL-6) and prostaglandins (PGE2), which drive tissue inflammation and bleeding [4, 13].